101 related articles for article (PubMed ID: 29271830)
1. Clinic-Based Evaluation of a Point-of-Care Creatinine Assay to Screen for Renal Impairment Among HIV-Positive Patients Receiving Tenofovir Disoproxil Fumarate.
Dorward J; Yende-Zuma N; Samsunder N; Karim QA; Drain PK; Garrett N
J Acquir Immune Defic Syndr; 2018 Apr; 77(4):e36-e39. PubMed ID: 29271830
[No Abstract] [Full Text] [Related]
2. Decline in Bone Mass With Tenofovir Disoproxil Fumarate/Emtricitabine Is Associated With Hormonal Changes in the Absence of Renal Impairment When Used by HIV-Uninfected Adolescent Boys and Young Men for HIV Preexposure Prophylaxis.
Havens PL; Stephensen CB; Van Loan MD; Schuster GU; Woodhouse LR; Flynn PM; Gordon CM; Pan CG; Rutledge B; Liu N; Wilson CM; Hazra R; Hosek SG; Anderson PL; Seifert SM; Kapogiannis BG; Mulligan K;
Clin Infect Dis; 2017 Feb; 64(3):317-325. PubMed ID: 28013265
[TBL] [Abstract][Full Text] [Related]
3. Long Term Exposure to Tenofovir Disoproxil Fumarate-Containing Antiretroviral Therapy Is Associated with Renal Impairment in an African Cohort of HIV-Infected Adults.
Agbaji OO; Abah IO; Ebonyi AO; Gimba ZM; Abene EE; Gomerep SS; Falang KD; Anejo-Okopi J; Agaba PA; Ugoagwu PO; Agaba EI; Imade GE; Sagay AS; Okonkwo P; Idoko JA; Kanki PJ
J Int Assoc Provid AIDS Care; 2019; 18():2325958218821963. PubMed ID: 30672363
[TBL] [Abstract][Full Text] [Related]
4. Brief Report: Frequency of Monitoring Kidney Function in HIV-Uninfected Persons Using Daily Oral Tenofovir Disoproxil Fumarate Pre-exposure Prophylaxis.
Mugwanya KK; Baeten JM; Wyatt C; Mugo NR; Celum CL; Ronald A; Kiarie J; Katabira E; Heffron R;
J Acquir Immune Defic Syndr; 2018 Feb; 77(2):206-211. PubMed ID: 29135656
[TBL] [Abstract][Full Text] [Related]
5. Tenofovir-associated renal toxicity in a cohort of HIV infected patients in Ghana.
Nartey ET; Tetteh RA; Yankey BA; Mantel-Teeuwisse AK; Leufkens HGM; Dodoo ANO; Lartey M
BMC Res Notes; 2019 Jul; 12(1):445. PubMed ID: 31331365
[TBL] [Abstract][Full Text] [Related]
6. Higher tenofovir exposure is associated with longitudinal declines in kidney function in women living with HIV.
Baxi SM; Scherzer R; Greenblatt RM; Minkoff H; Sharma A; Cohen M; Young MA; Abraham AG; Shlipak MG;
AIDS; 2016 Feb; 30(4):609-18. PubMed ID: 26558723
[TBL] [Abstract][Full Text] [Related]
7. Prospective Study to Assess Progression of Renal Markers after Interruption of Tenofovir due to Nephrotoxicity.
Bonjoch A; Echeverría P; Perez-Alvarez N; Puig J; Estany C; Clotet B; Negredo E
Biomed Res Int; 2016; 2016():4380845. PubMed ID: 28078289
[No Abstract] [Full Text] [Related]
8. Brief Report: Tenofovir-Associated Nephrotoxicity Among a US National Historical Cohort of HIV-Infected Veterans: Risk Modification by Concomitant Antiretrovirals.
LaFleur J; Bress AP; Esker S; Knippenberg K; Crook J; Nyman H; Bedimo R; Tebas P; Rosenblatt L
J Acquir Immune Defic Syndr; 2018 Mar; 77(3):325-330. PubMed ID: 29210830
[TBL] [Abstract][Full Text] [Related]
9. Cluster headache-like symptoms during treatment with tenofovir disoproxil fumarate and emtricitabine.
Citerne Q; Boyer L; Moreau E; Garon J; Gillet P; Petitpain N
AIDS; 2019 Jul; 33(9):1535-1536. PubMed ID: 31259768
[No Abstract] [Full Text] [Related]
10. Renal mitochondrial toxicity: effects of thymidine analogues and tenofovir disoproxil fumarate in African people with HIV.
Hunt M; Phillips R; Hardy Y; Owusu DO; Mitchelmore R; Durrani M; Payne BAI; Chadwick DR
AIDS; 2022 Jun; 36(7):1049-1051. PubMed ID: 35652677
[TBL] [Abstract][Full Text] [Related]
11. Proximal tubular dysfunction in a HIV-1 patient with coadministered tenofovir disoproxil-fumarate and ibuprofen.
Duim AR; Rokx C; van Gorp EC; Rijnders BJ
AIDS; 2015 Mar; 29(6):746-8. PubMed ID: 25849839
[No Abstract] [Full Text] [Related]
12. Plasma and Intracellular Pharmacokinetics of Tenofovir Disoproxil Fumarate 300 mg Every 48 Hours vs 150 mg Once Daily in HIV-Infected Adults With Moderate Renal Function Impairment.
Cressey TR; Avihingsanon A; Halue G; Leenasirimakul P; Sukrakanchana PO; Tawon Y; Jaisieng N; Jourdain G; Podany AT; Fletcher CV; Klinbuayaem V; Bowonwatanuwong C
Clin Infect Dis; 2015 Aug; 61(4):633-9. PubMed ID: 25921689
[TBL] [Abstract][Full Text] [Related]
13. Incidence and risk factors for tenofovir-associated renal toxicity in HIV-infected patients.
Quesada PR; Esteban LL; García JR; Sánchez RV; García TM; Alonso-Vega GG; Ferrández JS
Int J Clin Pharm; 2015 Oct; 37(5):865-72. PubMed ID: 26008219
[TBL] [Abstract][Full Text] [Related]
14. Impact of tenofovir dose adjustment on both estimated glomerular filtration rate and tenofovir trough concentration.
Bregigeon S; Solas C; Faucher O; Obry-Roguet V; Tamalet C; Poizot-Martin I
Antivir Ther; 2017; 22(6):529-533. PubMed ID: 28195560
[TBL] [Abstract][Full Text] [Related]
15. Brief Report: Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Adults With Renal Impairment: 96-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study.
Post FA; Tebas P; Clarke A; Cotte L; Short WR; Abram ME; Jiang S; Cheng A; Das M; Fordyce MW
J Acquir Immune Defic Syndr; 2017 Feb; 74(2):180-184. PubMed ID: 27673443
[TBL] [Abstract][Full Text] [Related]
16. Urinary β2 microglobulin can predict tenofovir disoproxil fumarate-related renal dysfunction in HIV-1-infected patients who initiate tenofovir disoproxil fumarate-containing antiretroviral therapy.
Nishijima T; Kurosawa T; Tanaka N; Kawasaki Y; Kikuchi Y; Oka S; Gatanaga H
AIDS; 2016 Jun; 30(10):1563-71. PubMed ID: 26919734
[TBL] [Abstract][Full Text] [Related]
17. Kidney dysfunction associated with tenofovir exposure in human immunodeficiency virus-1-infected Taiwanese patients.
Huang YS; Chan CK; Tsai MS; Lee KY; Lin SW; Chang SY; Hung CC; Chang SC
J Microbiol Immunol Infect; 2017 Oct; 50(5):595-603. PubMed ID: 26514942
[TBL] [Abstract][Full Text] [Related]
18. Renal outcomes in patients initiated on tenofovir disoproxil fumarate-based antiretroviral therapy at a community health centre in Malawi.
Chikwapulo B; Ngwira B; Sagno JB; Evans R
Int J STD AIDS; 2018 Jun; 29(7):650-657. PubMed ID: 29334883
[TBL] [Abstract][Full Text] [Related]
19. Low Risk of Proximal Tubular Dysfunction Associated With Emtricitabine-Tenofovir Disoproxil Fumarate Preexposure Prophylaxis in Men and Women.
Mugwanya K; Baeten J; Celum C; Donnell D; Nickolas T; Mugo N; Branch A; Tappero J; Kiarie J; Ronald A; Yin M; Wyatt C;
J Infect Dis; 2016 Oct; 214(7):1050-7. PubMed ID: 27029778
[TBL] [Abstract][Full Text] [Related]
20. Renal Toxicity of Concomitant Exposure to Tenofovir and Inhibitors of Tenofovir's Renal Efflux Transporters in Patients Infected With HIV Type 1.
Rokx C; Alshangi H; Verbon A; Zietse R; Hoorn EJ; Rijnders BJ
J Infect Dis; 2016 Feb; 213(4):561-8. PubMed ID: 26401025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
